Drug Combination Details
| General Information of the Combination (ID: C14683) | |||||
|---|---|---|---|---|---|
| Name | Scutellarin NP Info | + | Oxaliplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Activity | PKM | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | ||
| HT29 | CVCL_A8EZ | Colorectal adenocarcinoma | Mus musculus | |||
| In-vivo Model | For a xenograft model, 5 * 106 OR-SW480 cells were subcutaneously injected into the right armpit of 4-week-old female immunodeficient nude BALB/c mice. | |||||
| Experimental
Result(s) |
Scutellarin resensitizes oxaliplatin-resistant CRC cells to oxaliplatin treatment through inhibition of PKM2. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2. Mol Ther Oncolytics. 2021 Mar 17;21:87-97. | |||
